Synthesis of quinobenzoxazine analogues with topoisomerase II and quadruplex interactions for use as antineoplastic agents
Patent 6528517 Issued on March 4, 2003. Estimated Expiration Date: February 4, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/279, Polycyclo ring system having the six-membered hetero ring as one of the cyclos514/224.5, At least three cyclos in the polycyclo ring system514/253.08Having -C(=X)-, wherein X is chalcogen, bonded directly to carbon of the hetero ring of the quinoline ring system
The present invention discloses a novel quinobenzoxazine self-assembly complex on DNA and on the topoisomerase II-DNA complex. The related model is used to design a new series of quinobenzoxazines, pyridobenzophenoxazines, pyrridonaphthophenoxazines, and other related compounds that may exhibit anticancer or antibiotic activity. The anticancer activity of these compounds is thought to operate via stabilization of the topoisomerase II-DNA complex and/or interaction with G-quadruplexes, while the antibiotic activity of these compounds derives from their ability to inhibit gyrase, the bacterial type II topoisomerase.
Other References
Chen et al., "XB596, A Promising Bis-Naphthalimide Anti-Cancer Agent," Anti-Cancer Drugs, 4(4), 447-457, Aug. 1993
Chu and Maleczka Jr., "Synthetis of 4-0xo-4H-quino[2,3,4-Ij][1,4]-benoxazine-5-carboxylic acid derivatives," J. Heterocyclic Chem., 24:453-456, 1987
Chu et al., "Synthesis and antitumour activities of quinolone antineoplastic agents," Drugs Exptl. Clin. Res., 18:275-282, 1992
Chu et al., "Synthesis and antitumour activities of tetracyclic quinolone antineoplastic agents," Drugs Exptl. Clin. Res., 20:177-183, 1994
Clement et al., "Biological characterization of a novel antitumour quinolone," Cancer Res., 55:830-835, 1995
Fan et al., "Self-assembly of a quinobenzoxazine-Mg2+ complex on DNA: a new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinolone bacterial gyrase-DNA complex," J. Med. Chem., 38:408-424, 1995
Fedoroff et al., "NMR-based model of a telomerase-inhibiting compound bound to g-quadruplex DNA," Biochemistry, 37:12367-12374, 1998
Han et al., "A DNA polymerase stop assay for Q-quadruplex-interactive compounds," Nucelic Acids Research, 27(2):537-542, 1999
Hansen et al., "Molecular details of the structure of a psorospermin-DNA covalent/intercalation complex and associated DNA sequence selectivity," J. Am. Chem. Soc., 118:5553-5561, 1996
Henderson et al., "Telomere G-strand structure and function analyzed by chemical protection, base analogue substitution, and utilization by telomerse in vitro," Biochemistry, 29:732-737, 1990
Kwok et al., "Topoisomerase II-mediated site-directed alkylation of DNA by psorospermin and its use in mapping other topoisomerase II poison binding sites," Proc. Natl. Acad. Sci. U.S.A., 95:13531-13536, 1998
Kwok and Hurley, "Topoisomerase II site-directed alkylation of DNA by psorospermin and its effect on topoisomerase II-mediated DNA cleavage," J. Biol. Chem., 49:33020-33026, 1998
Kwok et al., "Structural insight into a quinolone-topoisomerase II-DNA complex," The J. of Bio. Chem., 274:1-10, 1999
MacDonald et al., "A solid phase approach to quinolones using the Diversomer.RTM. technology," Tetrahedron Lett., 37:4815-4818, 1996
Maxam and Gilbert, "Sequencing end-labeled DNA with base-specific chemical cleavages," Methods Enzymol., 65:499-560, 1980
Mergny and Helene, "G-quadruplex DNA: a target for drug design," Nature Medicine, 4:1366-1367, 1998
Mitscher et al., "Structure-activity relationships of fluoro-4-quinolones," Springer-Verlag: New York, 1990, pp. 115-146
Morin, "Is telomerase a universal cancer target?" J. Natl. Cancer Inst., 87:859-861, 1995
Mosmann, "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays," J. Immunol. Methods, 65(1-2):55-63, 1983
Parkinson, "Do telomerase antagonists represent a novel anti-cancer strategy?" Br. J. Cancer, 73:1-4, 1996
Radl and Zikan, "Synthesis and antimicrobial activity of some 3-OXO-3H-pyrido[3,2,1-kl]phenoxazine-2-carboxylic acids," Collect. Czech. Chem. Commun., 54:506-515, 1989
Permana et al., "Quinobenoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors," Biochemistry, 33:11333-11339, 1994
Raymond et al., "Agents that target telomerase and telomeres," Curr. Opinion Biotch., 7:583-591, 1996
Rodi et al., "Screening of a library of phage-displayed peptides identifies human Bcl-2 as a taxol-binding protein," J. Mol. Biol., 285:197, 1999
Rubinstein et al., "Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel for human tumor cell lines," J. Natl. Cancer Inst., 82(13):1113-1118, 1990
Shen et al., "Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA," Biochemistry, 28:3879-3885, 1989a
Shen et al., "Mechanism of quinolone inhibition of DNA gyrase," J. Biol. Chem., 264:2973-2978, 1989b
Shen et al., "Mechanism of inhibition of DNA gyrase by quinlone antibacterials: a cooperative drug-DNA binding model," Biochemistry, 28:3886-3894, 1989c
Sun et al., "Inhibition of human telomerase by a g-quadruplex-interactive compound," J. Med. Chem., 40:2113-2116, 1997
Wang and Patel, "Solution structure of the human telomeric repeat d[AG3 (T2 AG3)3 ] g-tetraplex," Structure, 1:263-282, 1993
Weitzmann et al., "The development and use of a DNA polymerase arrest assay for the evaluation of parameters affecting intrastrand tetraplex formation," J. Biol. Chem., 271:20958-20964, 1996
Wheelhouse et al., "Cationic porphyrins as telomerase inhibitors: the interaciton of tetra-(N-methyl-4-pyridyl)porphine with Quadruplex DNA," J. Am. Chem. Soc., 120:3261-3262, 1998
Willmott and Maxwell, "A single point mutation in the DNA gyrase a protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex," Anitmicrob. Agents Chemother., 37:126-127, 1993
Yu et al., "Evidence of the formation of 2:2 drug-Mg2+ dimers in solution and for the formation of dimeric drug complexes on DNA form the DNA-accelerated photochemical reaction of antineoplastic quinobenzoxazines," J. Am. Chem. Soc., 118:7040-7048, 1996
Zeng et al., "Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model," J. Med. Chem., 41:4273-4278, 1998
Yamakuchi et al., "New quinolones, ofloxacin and levofloxain, inhibit telomerase activity in transitional cell carcinoma cell lines,"Abstract, Cancer Letters, 119(2):213-219, 1997
Kaufmann and Hancock, "Topoisomerase II as a target for anticancer chemtherapy," Abstract, Acta Bicochimica Polonica, 42(4):381-393, 1995
Ebisuno et al., "The cytotoxic effects of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro," Cancer, 80(12):2263-2267, 1997
Wentland et al., "Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8-difluro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3 -quinolinecarboxylic acid and related derivatives," J. Med. Chem., 36:2801-2809, 1993
Hertzberg et al., "Antineoplastic agents," Ann. Rep. In Med. Chem., 28:167-176, 1993
Palmer et al., "Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carbonxamides," J. Med. Chem., 31:707-712, 1988
Hsiung et al., "A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria," The J. of Biol. Chem., 270(35):20359-20364, 1995
Khac and Moreau, "Interaction between fluoroquinolones, Mg2+, DNA and DNA gyrase, studied by phase partitioning in an aqueous two-phase system and by affinity chromatography," J. of Chromatography, 668:241-247, 1994
Chung et al., "p-Quinone methides as geometric analogues of quinolone carboxylate antibacterials," Bioorganic & Medicinal Chem. Letters, 6(12):1309-1312, 1996
Lecomte et al., "NMR investigation of pefloxacin-cation-DNA interactions: the essential role of Mg2+," Intl. J. of Pharm., 164:57-65, 1998
Rodighiero et al., "Angular furoquinolones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies," J. Med. Chem., 39:1293-1302, 1996
Llorente et al., "Using SAR and QSAR analysis to model the activity and structure fo the quinolone-DNA complex," Bioorganic & Medicinal Chem., 4(1):61-71, 1996
Lecomte and Chenon, "NMR investigation of pefloxacin/cation/DNA interactions. Mg2+ and Ca2+ binding," Intl. J. of Pharm., 139:105-112, 1996
Lecomte et al., "Effect of magnesium complexation by fluoroquinolones on their antibacterial properties," Antimicrobial Agents and Chemo., 38(12):2810-2816, 1994
Khac and Moreau, "Interactions between fluoroquinolones, Mg2+, DNA and DNA gyrase, studied by phase partitioning in an aqueous two-phase system and by affinity chromotagraphy," J. of Chromatography, 668:241-247, 199
February 4, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
